Solution to Series 1

Size: px
Start display at page:

Download "Solution to Series 1"

Transcription

1 Dr A Hauser Analysis AS 2018 Solution to Series 1 1 a) We can compute the cumulative hazard function: We know that H(t) = t 0 h(u)du = t H(t) = log S(t) ( S(t) = exp t ) The following plot shows the survivor function for different : S(t) Survivor function = 2 = 1 = b) The density f(t) is given by f(t) = h(t) S(t) f(t) = 1 ( exp t ) t The cumulative distribution function F (t) is given by F (t) = 1 S(t) ( F (t) = 1 exp t ) c) f(t) t is the unconditional ( a priori ) probability that the nucleus decays in the small time interval [t, t + t] h(t) t, in contrast, is the probability that the nucleus decays in the interval [t, t + t], given that is has not decayed yet at time t 2 x i d i n i p i Ŝ(x i ) = P(X > x i ) se(ŝ(x i)) /8 7/8 = = /8 = /6 7/8 5/6 = 35/48 = = /5 35/48 3/5 = 7/16 = = /16 = /2 7/16 1/2 = 7/32 = =

2 Calculation in R: > x <- c(1, 1, 2, 4, 4, 4, 6, 9) > status <- c(1, 0, 1, 1, 1, 0, 1, 1) # 0 for censored > rsf <- survfit(surv(x, status) 1, conftype = "none") > summary(rsf) survfit(formula = Surv(x, status) ~ 1, conftype = "none") time nrisk nevent survival stderr NA R-Code for drawing the survival curve: > plot(rsf, xlab = "", ylab = "") 3 a) > library(survival) > turl <- " > ddiabetes <- readtable(turl, header = TRUE, sep = ",") > rsv <- survfit(surv(lzeit, tod) ~ 1, type = "kaplan-meier", ddiabetes) > plot(rsv, confint = FALSE, xlab = "", ylab = "") b) The groups (diabetic, non diabetic) have different KM-curves The people in the diabetes group, seem to die sooner > rsv2 <- survfit(surv(lzeit, tod) ~ diab, data = ddiabetes) > plot(rsv2, confint = FALSE, lty = 1:2, xlab = "", ylab = "") > legend(3000, 08, c("no diabetes", "diabetes"), lty = 1:2)

3 3 no diabetes diabetes c) > rsv0 <- summary(survfit(surv(lzeit, tod) ~ 1, subset = diab == 0, conftype = "n", data = ddiabetes), censor = TRUE) > ttime0 <- rsv0$time > tweight0 <- rsv0$nevent / rsv0$nrisk > tsmooth0 <- density(ttime0, kernel = "epanechnikov", weights = tweight0, n = 100, from = 0, to = 4000) > plot(tsmooth0$x, tsmooth0$y, type = "l", ylim = c(0, 00018), main = "Kernel estimators of hazards", xlab = "time", ylab = "Smoothed hazard") > rsv1 <- summary(survfit(surv(lzeit, tod) ~ 1, subset = diab == 1, conftype = "n", data = ddiabetes), censor = TRUE) > ttime1 <- rsv1$time > tweight1 <- rsv1$nevent / rsv1$nrisk > tsmooth1 <- density(ttime1, kernel = "epanechnikov", weights = tweight1, n = 100, from = 0, to = 4000) > lines(tsmooth1$x, tsmooth1$y, lty = 2) > legend(0, 00018, c('no diabetes', 'diabetes'), lty = 1:2) Kernel estimators of hazards Smoothed hazard no diabetes diabetes time In the graph above, we can see, that the risk for the people not having diabetes is estimated to be zero after approx 3000 days The ratio is then no longer meaningful > plot(tsmooth0$x, tsmooth1$y / tsmooth0$y, xlim = c(0, 2800), ylim = c(0, 10), type = "l", main = "Ratio of Smoothed Hazards", xlab = "time", ylab = "hazard ratio")

4 4 hazard ratio Ratio of Smoothed Hazards time d) The Log-Rank-Test (p-value=002) confirms the difference seen by eye: > survdiff(surv(lzeit, tod) ~ diab, data = ddiabetes) survdiff(formula = Surv(lzeit, tod) ~ diab, data = ddiabetes) diab= diab= Chisq= 55 on 1 degrees of freedom, p= 002 e) The plot shows a difference between diabetics and non diabetics Especially the young non diabetics have a considerable larger chance of survival compared to the other groups There is an interesting structure in the diabetics group The young diabetics have a clearly larger chance of survival in the first years after the operation Then their curves cross and the young diabetics die sooner Here we should check why this can be like that > rsv4b <- survfit(surv(lzeit, tod) ~ diab + strata(altgr), data = ddiabetes) > summary(rsv4b) > plot(rsv4b, lty = 1:4) > legend(3000, 095, legend = c("(0,0)", "(0,1)", "(1,0)", "(1,1)"), lty = 1:4) > text(3500, 099, "(diab,altgr)") (diab,altgr) (0,0) (0,1) (1,0) (1,1) When we stratify by gender, there is a group with only 3 observations, 2 of which censored (the censored observations are displayed by a + in the survival curves, this can be done with the argument marktime = TRUE in the plot()-function) This curve (female, non diabetics) is thus little meaningful

5 5 > rsv4a <- survfit(surv(lzeit, tod) ~ diab + strata(sex), data = ddiabetes) > summary(rsv4a) > plot(rsv4a, marktime = TRUE, lty = 1:4) > legend(3000, 09, legend = c("(0,0)", "(0,1)", "(1,0)", "(1,1)"), lty = 1:4) > text(3500, 095, "(diab,sex)") (diab,sex) (0,0) (0,1) (1,0) (1,1) f) Stratifying by age: > survdiff(surv(lzeit,tod) ~ diab + strata(altgr), data = ddiabetes) survdiff(formula = Surv(lzeit, tod) ~ diab + strata(altgr), data = ddiabetes) diab= diab= Chisq= 43 on 1 degrees of freedom, p= 004 The difference in survival between diabetics and non-diabetics is also significant, if we stratify by age Stratifying by gender: > survdiff(surv(lzeit,tod) ~ diab + strata(sex), data = ddiabetes) survdiff(formula = Surv(lzeit, tod) ~ diab + strata(sex), data = ddiabetes) diab= diab= Chisq= 49 on 1 degrees of freedom, p= 003 Again the difference is significant Age and sex seem to play a secondary role in this case This may be surprising and we will come back to this later 4 a) Type I censored data because animals enter the study at the same time and are observed for a fixed period of time b) Type II censored data because animals enter the study at the same time but are observed until a fixed portion of the subjects have died

dataset1 <- read.delim("c:\dca_example_dataset1.txt", header = TRUE, sep = "\t") attach(dataset1)

dataset1 <- read.delim(c:\dca_example_dataset1.txt, header = TRUE, sep = \t) attach(dataset1) Worked examples of decision curve analysis using R A note about R versions The R script files to implement decision curve analysis were developed using R version 2.3.1, and were tested last using R version

More information

Biostatistics II

Biostatistics II Biostatistics II 514-5509 Course Description: Modern multivariable statistical analysis based on the concept of generalized linear models. Includes linear, logistic, and Poisson regression, survival analysis,

More information

Backcalculating HIV incidence and predicting AIDS in Australia, Cambodia and Vietnam. Australia

Backcalculating HIV incidence and predicting AIDS in Australia, Cambodia and Vietnam. Australia Backcalculating HIV incidence and predicting AIDS in Australia, Cambodia and Vietnam The aim of today s practical is to give you some hands-on experience with a nonparametric method for backcalculating

More information

Package prognosticroc

Package prognosticroc Type Package Package prognosticroc February 20, 2015 Title Prognostic ROC curves for evaluating the predictive capacity of a binary test Version 0.7 Date 2013-11-27 Author Y. Foucher

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patientlevel data. Published online

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B

More information

cloglog link function to transform the (population) hazard probability into a continuous

cloglog link function to transform the (population) hazard probability into a continuous Supplementary material. Discrete time event history analysis Hazard model details. In our discrete time event history analysis, we used the asymmetric cloglog link function to transform the (population)

More information

Cumulative metformin use and its impact on survival in gastric cancer patients after INDEX

Cumulative metformin use and its impact on survival in gastric cancer patients after INDEX Supplementary Data Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy Lee et al. INDEX Supplementary Figure 1. Survival analysis according to stage : DM versus

More information

Statistical Methods for the Evaluation of Treatment Effectiveness in the Presence of Competing Risks

Statistical Methods for the Evaluation of Treatment Effectiveness in the Presence of Competing Risks Statistical Methods for the Evaluation of Treatment Effectiveness in the Presence of Competing Risks Ravi Varadhan Assistant Professor (On Behalf of the Johns Hopkins DEcIDE Center) Center on Aging and

More information

TWISTED SURVIVAL: IDENTIFYING SURROGATE ENDPOINTS FOR MORTALITY USING QTWIST AND CONDITIONAL DISEASE FREE SURVIVAL. Beth A.

TWISTED SURVIVAL: IDENTIFYING SURROGATE ENDPOINTS FOR MORTALITY USING QTWIST AND CONDITIONAL DISEASE FREE SURVIVAL. Beth A. TWISTED SURVIVAL: IDENTIFYING SURROGATE ENDPOINTS FOR MORTALITY USING QTWIST AND CONDITIONAL DISEASE FREE SURVIVAL by Beth A. Zamboni BS Statistics, University of Pittsburgh, 1997 MS Biostatistics, Harvard

More information

Evaluating the Predictors of Chronic Kidney Disease Identification Number 8806 Biostatistics 699 Project

Evaluating the Predictors of Chronic Kidney Disease Identification Number 8806 Biostatistics 699 Project Evaluating the Predictors of Chronic Kidney Disease Identification Number 8806 Biostatistics 699 Project 1 01.29.2008 Appendix A contains supplemental results Appendix B contains analysis code Abstract:

More information

Package Actigraphy. R topics documented: January 15, Type Package Title Actigraphy Data Analysis Version 1.3.

Package Actigraphy. R topics documented: January 15, Type Package Title Actigraphy Data Analysis Version 1.3. Type Package Title Actigraphy Data Analysis Version 1.3.2 Date 2016-01-14 Package Actigraphy January 15, 2016 Author William Shannon, Tao Li, Hong Xian, Jia Wang, Elena Deych, Carlos Gonzalez Maintainer

More information

Statistical Models for Censored Point Processes with Cure Rates

Statistical Models for Censored Point Processes with Cure Rates Statistical Models for Censored Point Processes with Cure Rates Jennifer Rogers MSD Seminar 2 November 2011 Outline Background and MESS Epilepsy MESS Exploratory Analysis Summary Statistics and Kaplan-Meier

More information

Package wally. May 25, Type Package

Package wally. May 25, Type Package Type Package Package wally May 25, 2017 Title The Wally Calibration Plot for Risk Prediction Models Version 1.0.9 Date 2017-04-28 Author Paul F Blanche , Thomas A. Gerds

More information

Common Misunderstandings of Survival Time Analysis

Common Misunderstandings of Survival Time Analysis Common isunderstandings of Survival Time Analysis ilensu Shanyinde Centre for Statistics in edicine University of Oxford 2 nd April 2012 Outline Introduction Essential features of the Kaplan-eier survival

More information

R/Bioconductor Center for Genomic Sciences Universidad Nacional Autónoma de México

R/Bioconductor Center for Genomic Sciences Universidad Nacional Autónoma de México R/Bioconductor Center for Genomic Sciences Universidad Nacional Autónoma de México Daniela Azucena García Soriano, dgarcia@lcg.unam.mx Yuvia Alhelí Pérez Rico, yperez@lcg.unam.mx October 23, 2009 Abstract

More information

Survival analysis beyond the Cox-model

Survival analysis beyond the Cox-model Survival analysis beyond the Cox-model Hans C. van Houwelingen Department of Medical Statistics Leiden University Medical Center The Netherlands jcvanhouwelingen@lumc.nl http://www.medstat.medfac.leidenuniv.nl/ms/hh/

More information

The Statistical Analysis of Failure Time Data

The Statistical Analysis of Failure Time Data The Statistical Analysis of Failure Time Data Second Edition JOHN D. KALBFLEISCH ROSS L. PRENTICE iwiley- 'INTERSCIENCE A JOHN WILEY & SONS, INC., PUBLICATION Contents Preface xi 1. Introduction 1 1.1

More information

A Handbook of Statistical Analyses Using R. Brian S. Everitt and Torsten Hothorn

A Handbook of Statistical Analyses Using R. Brian S. Everitt and Torsten Hothorn A Handbook of Statistical Analyses Using R Brian S. Everitt and Torsten Hothorn CHAPTER 11 Analysing Longitudinal Data II Generalised Estimation Equations: Treating Respiratory Illness and Epileptic Seizures

More information

Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD,

Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, MD, Paul Hebert, PhD, Michael C. Iannuzzi, MD, and

More information

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule

More information

SYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301

SYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301 SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in

More information

Supplementary. properties of. network types. randomly sampled. subsets (75%

Supplementary. properties of. network types. randomly sampled. subsets (75% Supplementary Information Gene co-expression network analysis reveals common system-level prognostic genes across cancer types properties of Supplementary Figure 1 The robustness and overlap of prognostic

More information

Methods for adjusting survival estimates in the presence of treatment crossover a simulation study

Methods for adjusting survival estimates in the presence of treatment crossover a simulation study Methods for adjusting survival estimates in the presence of treatment crossover a simulation study Nicholas Latimer, University of Sheffield Collaborators: Paul Lambert, Keith Abrams, Michael Crowther

More information

Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.

Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,

More information

From Biostatistics Using JMP: A Practical Guide. Full book available for purchase here. Chapter 1: Introduction... 1

From Biostatistics Using JMP: A Practical Guide. Full book available for purchase here. Chapter 1: Introduction... 1 From Biostatistics Using JMP: A Practical Guide. Full book available for purchase here. Contents Dedication... iii Acknowledgments... xi About This Book... xiii About the Author... xvii Chapter 1: Introduction...

More information

Six Sigma Glossary Lean 6 Society

Six Sigma Glossary Lean 6 Society Six Sigma Glossary Lean 6 Society ABSCISSA ACCEPTANCE REGION ALPHA RISK ALTERNATIVE HYPOTHESIS ASSIGNABLE CAUSE ASSIGNABLE VARIATIONS The horizontal axis of a graph The region of values for which the null

More information

Package mediation. September 18, 2009

Package mediation. September 18, 2009 Version 2.1 Date 2009-09-14 Title R Package for Causal Mediation Analysis Package mediation September 18, 2009 Author Luke Keele , Dustin Tingley , Teppei

More information

Development and Validation of a Clinical Decision Score to Maximize Benefit and Minimize Harm from Intensive Blood Pressure Treatment

Development and Validation of a Clinical Decision Score to Maximize Benefit and Minimize Harm from Intensive Blood Pressure Treatment Development and Validation of a Clinical Decision Score to Maximize Benefit and Minimize Harm from Intensive Blood Pressure Treatment Sanjay Basu, MD, PhD basus@stanford.edu Disclosures and conflicts of

More information

Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel

Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel Jane Lange March 22, 2017 1 Acknowledgements Many thanks to the multiple project

More information

Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma

Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma Karia, et al Methods Details of data collectionfeatures of primary tumors including anatomic

More information

Name: BIOS 703 MIDTERM EXAMINATIONS (5 marks per question, total = 100 marks)

Name: BIOS 703 MIDTERM EXAMINATIONS (5 marks per question, total = 100 marks) Name: BIOS 703 MIDTERM EXAMINATIONS (5 marks per question, total = 100 marks) You will have 75 minutest to complete this examination. Some of the questions refer to Crizotinib in ROS1- Rearranged Non Small-

More information

Introduction to Meta-analysis of Accuracy Data

Introduction to Meta-analysis of Accuracy Data Introduction to Meta-analysis of Accuracy Data Hans Reitsma MD, PhD Dept. of Clinical Epidemiology, Biostatistics & Bioinformatics Academic Medical Center - Amsterdam Continental European Support Unit

More information

National Lung Screening Trial Results

National Lung Screening Trial Results National Lung Screening Trial Results Ella A. Kazerooni, M.D. Professor & Director Cardiothoracic Radiology Associate Chair for Clinical Affairs University of Michigan NLST STOPPED! Lung cancer trial results

More information

Data Exploration and Visualization

Data Exploration and Visualization Data Exploration and Visualization Bu eğitim sunumları İstanbul Kalkınma Ajansı nın 2016 yılı Yenilikçi ve Yaratıcı İstanbul Mali Destek Programı kapsamında yürütülmekte olan TR10/16/YNY/0036 no lu İstanbul

More information

Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study

Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study Julia Hippisley-Cox, 1,2 Carol Coupland 1 1 Division of Primary Care, University

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Jänne PA, van den Heuvel MM, Barlesi F, et al. Effect of selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRASmutant

More information

Overview. All-cause mortality for males with colon cancer and Finnish population. Relative survival

Overview. All-cause mortality for males with colon cancer and Finnish population. Relative survival An overview and some recent advances in statistical methods for population-based cancer survival analysis: relative survival, cure models, and flexible parametric models Paul W Dickman 1 Paul C Lambert

More information

Computer Age Statistical Inference. Algorithms, Evidence, and Data Science. BRADLEY EFRON Stanford University, California

Computer Age Statistical Inference. Algorithms, Evidence, and Data Science. BRADLEY EFRON Stanford University, California Computer Age Statistical Inference Algorithms, Evidence, and Data Science BRADLEY EFRON Stanford University, California TREVOR HASTIE Stanford University, California ggf CAMBRIDGE UNIVERSITY PRESS Preface

More information

Organizing Data. Types of Distributions. Uniform distribution All ranges or categories have nearly the same value a.k.a. rectangular distribution

Organizing Data. Types of Distributions. Uniform distribution All ranges or categories have nearly the same value a.k.a. rectangular distribution Organizing Data Frequency How many of the data are in a category or range Just count up how many there are Notation x = number in one category n = total number in sample (all categories combined) Relative

More information

Modelling the recurrence of bladder cancer

Modelling the recurrence of bladder cancer Modelling the recurrence of bladder cancer Gregorio Rubio 1, Cristina Santamaría 1, Belén García 1, and José Luis Pontones 2 1 Matemática multidisciplinar Universidad Politécnica Valencia (Spain) (e-mail:

More information

4. STATA output of the analysis

4. STATA output of the analysis Biostatistics(1.55) 1. Objective: analyzing epileptic seizures data using GEE marginal model in STATA.. Scientific question: Determine whether the treatment reduces the rate of epileptic seizures. 3. Dataset:

More information

The role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy

The role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David

More information

An Overview of Survival Statistics in SEER*Stat

An Overview of Survival Statistics in SEER*Stat An Overview of Survival Statistics in SEER*Stat National Cancer Institute SEER Program SEER s mission is to provide information on cancer statistics in an effort to reduce the burden of cancer among the

More information

Application of Artificial Neural Network-Based Survival Analysis on Two Breast Cancer Datasets

Application of Artificial Neural Network-Based Survival Analysis on Two Breast Cancer Datasets Application of Artificial Neural Network-Based Survival Analysis on Two Breast Cancer Datasets Chih-Lin Chi a, W. Nick Street b, William H. Wolberg c a Health Informatics Program, University of Iowa b

More information

The rmeta Package February 17, 2001

The rmeta Package February 17, 2001 R topics documented: The rmeta Package February 17, 2001 catheter......................................... 1 funnelplot........................................ 2 meta.dsl........................................

More information

The results of the clinical exam first have to be turned into a numeric variable.

The results of the clinical exam first have to be turned into a numeric variable. Worked examples of decision curve analysis using Stata Basic set up This example assumes that the user has installed the decision curve ado file and has saved the example data sets. use dca_example_dataset1.dta,

More information

EMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.

EMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

Supplementary Materials

Supplementary Materials Supplementary Materials Supplementary figure 1. Taxonomic representation summarized at genus level. Fecal microbiota from a separate set of Jackson and Harlan mice prior to irradiation. A taxon was included

More information

Introduction At times when pollen is scarce in the natural environment

Introduction At times when pollen is scarce in the natural environment Artificial Bee Diets Taryn Major Linda Eaton Kathy Haskard Philip Vlaskovsky Rob Manning (Department of Agriculture and Food) Introduction At times when pollen is scarce in the natural environment Bees

More information

Readings: Textbook readings: OpenStax - Chapters 1 11 Online readings: Appendix D, E & F Plous Chapters 10, 11, 12 and 14

Readings: Textbook readings: OpenStax - Chapters 1 11 Online readings: Appendix D, E & F Plous Chapters 10, 11, 12 and 14 Readings: Textbook readings: OpenStax - Chapters 1 11 Online readings: Appendix D, E & F Plous Chapters 10, 11, 12 and 14 Still important ideas Contrast the measurement of observable actions (and/or characteristics)

More information

Supplemental Table 1: NHLBI Transplant Protocols

Supplemental Table 1: NHLBI Transplant Protocols Supplemental Table 1: NHLBI Transplant Protocols N.B: Second column ( n ) lists number of patients for whom pre-sct samples could be identified. In addition to above, two protocols enrolled a single patient

More information

Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery

Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery Impact of Screening Colonoscopy on Outcomes in Colon Cancer Surgery The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation

More information

Application of Cox Regression in Modeling Survival Rate of Drug Abuse

Application of Cox Regression in Modeling Survival Rate of Drug Abuse American Journal of Theoretical and Applied Statistics 2018; 7(1): 1-7 http://www.sciencepublishinggroup.com/j/ajtas doi: 10.11648/j.ajtas.20180701.11 ISSN: 2326-8999 (Print); ISSN: 2326-9006 (Online)

More information

17/10/2012. Could a persistent cough be whooping cough? Epidemiology and Statistics Module Lecture 3. Sandra Eldridge

17/10/2012. Could a persistent cough be whooping cough? Epidemiology and Statistics Module Lecture 3. Sandra Eldridge Could a persistent be whooping? Epidemiology and Statistics Module Lecture 3 Sandra Eldridge Aims of lecture To explain how to interpret a confidence interval To explain the different ways of comparing

More information

A Study on Type 2 Diabetes Mellitus Patients Using Regression Model and Survival Analysis Techniques

A Study on Type 2 Diabetes Mellitus Patients Using Regression Model and Survival Analysis Techniques Available online at www.ijpab.com Shaik et al Int. J. Pure App. Biosci. 6 (1): 514-522 (2018) ISSN: 2320 7051 DOI: http://dx.doi.org/10.18782/2320-7051.5999 ISSN: 2320 7051 Int. J. Pure App. Biosci. 6

More information

Statistics and Epidemiology Practice Questions

Statistics and Epidemiology Practice Questions 1. Which of the following is not considered a measure of central tendency? a. Median b. Range c. Mode d. Average 2. Given the following set of values, what is the median? 4 5 9 3 8 3 7 1 5 3 a. 3 b. 5

More information

BRaf V600E cooperates with Pten silencing to elicit metastatic melanoma (Nature Genetics Supplementary Information)

BRaf V600E cooperates with Pten silencing to elicit metastatic melanoma (Nature Genetics Supplementary Information) BRaf V600E cooperates with Pten silencing to elicit metastatic melanoma (Nature Genetics Supplementary Information) David Dankort, David P. Curley, Robert A. Cartlidge, Betsy Nelson, Anthony N. Karnezis,

More information

# Assessment of gene expression levels between several cell group types is a common application of the unsupervised technique.

# Assessment of gene expression levels between several cell group types is a common application of the unsupervised technique. # Aleksey Morozov # Microarray Data Analysis Using Hierarchical Clustering. # The "unsupervised learning" approach deals with data that has the features X1,X2...Xp, but does not have an associated response

More information

Package p3state.msm. R topics documented: February 20, 2015

Package p3state.msm. R topics documented: February 20, 2015 Package p3state.msm February 20, 2015 Type Package Depends R (>= 2.8.1),survival,base Title Analyzing survival data Version 1.3 Date 2012-06-03 Author Luis Meira-Machado and Javier Roca-Pardinas

More information

Using the Palliative Performance Scale to Provide Meaningful Survival Estimates

Using the Palliative Performance Scale to Provide Meaningful Survival Estimates 134 Journal of Pain and Symptom Management Vol. 38 No. 1 July 2009 Original Article Using the Palliative Performance Scale to Provide Meaningful Survival Estimates Francis Lau, PhD, Michael Downing, MD,

More information

IDENTIFYING STAGE 1 HEPATOCELLULAR CARCINOMA PATIENTS WITH POOR PROGNOSIS

IDENTIFYING STAGE 1 HEPATOCELLULAR CARCINOMA PATIENTS WITH POOR PROGNOSIS IDENTIFYING STAGE 1 HEPATOCELLULAR CARCINOMA PATIENTS WITH POOR PROGNOSIS J. B. NATION Abstract. Aim: The purpose of this note is to show that survival times for stage 1 HCC patients has a bimodal distribution,

More information

Hour 2: lm (regression), plot (scatterplots), cooks.distance and resid (diagnostics) Stat 302, Winter 2016 SFU, Week 3, Hour 1, Page 1

Hour 2: lm (regression), plot (scatterplots), cooks.distance and resid (diagnostics) Stat 302, Winter 2016 SFU, Week 3, Hour 1, Page 1 Agenda for Week 3, Hr 1 (Tuesday, Jan 19) Hour 1: - Installing R and inputting data. - Different tools for R: Notepad++ and RStudio. - Basic commands:?,??, mean(), sd(), t.test(), lm(), plot() - t.test()

More information

Chapter 2 Psychological Research, Methods and Statistics

Chapter 2 Psychological Research, Methods and Statistics Chapter 2 Psychological Research, Methods and Statistics Section 1- What is Research? Psychologists must first decide how to approach the research issue. Then psychologists conduct the research in one

More information

Statistical Challenges in Immunotherapy: Non Proportional Hazard Model. BBS / PSI CIT event 15-June-2017, Basel Claude BERGE, Roche

Statistical Challenges in Immunotherapy: Non Proportional Hazard Model. BBS / PSI CIT event 15-June-2017, Basel Claude BERGE, Roche Statistical Challenges in Immunotherapy: Non Proportional Hazard Model BBS / PSI CIT event 15-June-2017, Basel Claude BERGE, Roche 1 Statistical Challenges Biomarker Efficacy Endpoint Study Design & Analysis

More information

APPENDIX N. Summary Statistics: The "Big 5" Statistical Tools for School Counselors

APPENDIX N. Summary Statistics: The Big 5 Statistical Tools for School Counselors APPENDIX N Summary Statistics: The "Big 5" Statistical Tools for School Counselors This appendix describes five basic statistical tools school counselors may use in conducting results based evaluation.

More information

Part [1.0] Introduction to Development and Evaluation of Dynamic Predictions

Part [1.0] Introduction to Development and Evaluation of Dynamic Predictions Part [1.0] Introduction to Development and Evaluation of Dynamic Predictions A Bansal & PJ Heagerty Department of Biostatistics University of Washington 1 Biomarkers The Instructor(s) Patrick Heagerty

More information

Case Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company

Case Studies in Bayesian Augmented Control Design. Nathan Enas Ji Lin Eli Lilly and Company Case Studies in Bayesian Augmented Control Design Nathan Enas Ji Lin Eli Lilly and Company Outline Drivers for innovation in Phase II designs Case Study #1 Pancreatic cancer Study design Analysis Learning

More information

Arbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia

Arbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia THE VALUE OF 24 H HEART RATE VARIABILITY IN PREDICTING THE MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND SYSTOLIC DYSFUNCTION IN BETA-BLOCKING BLOCKING ERA Arbolishvili GN, Mareev VY Institute of Clinical

More information

Cancer Treatment by Alternating Electric Fields (TTFields); Physical Basis & Clinical Trial Results. Madrid, March 2015

Cancer Treatment by Alternating Electric Fields (TTFields); Physical Basis & Clinical Trial Results. Madrid, March 2015 1 Cancer Treatment by Alternating Electric Fields (TTFields); Physical Basis & Clinical Trial Results Madrid, March 2015 2 Cancer Treatments Surgical - whenever possible, Effective mostly in Early stages,

More information

UNIT V: Analysis of Non-numerical and Numerical Data SWK 330 Kimberly Baker-Abrams. In qualitative research: Grounded Theory

UNIT V: Analysis of Non-numerical and Numerical Data SWK 330 Kimberly Baker-Abrams. In qualitative research: Grounded Theory UNIT V: Analysis of Non-numerical and Numerical Data SWK 330 Kimberly Baker-Abrams In qualitative research: analysis is on going (occurs as data is gathered) must be careful not to draw conclusions before

More information

DISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board

DISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board INTERIM ANALYSIS OF THE PHASE 3 ADAPT TRIAL EVALUATING ROCAPULDENCEL-T (AGS-003), AN INDIVIDUALIZED IMMUNOTHERAPY FOR THE TREATMENT OF NEWLY-DIAGNOSED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)

More information

LOGO. Statistical Modeling of Breast and Lung Cancers. Cancer Research Team. Department of Mathematics and Statistics University of South Florida

LOGO. Statistical Modeling of Breast and Lung Cancers. Cancer Research Team. Department of Mathematics and Statistics University of South Florida LOGO Statistical Modeling of Breast and Lung Cancers Cancer Research Team Department of Mathematics and Statistics University of South Florida 1 LOGO 2 Outline Nonparametric and parametric analysis of

More information

Making Inferences from Experiments

Making Inferences from Experiments 11.6 Making Inferences from Experiments Essential Question How can you test a hypothesis about an experiment? Resampling Data Yield (kilograms) Control Group Treatment Group 1. 1.1 1.2 1. 1.5 1.4.9 1.2

More information

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer

More information

Rimegepant Pivotal Phase 3 Trial Results - Conference Call March 26, Biohaven

Rimegepant Pivotal Phase 3 Trial Results - Conference Call March 26, Biohaven Rimegepant Pivotal Phase 3 Trial Results - Conference Call March 26, 2018 1 Forward-Looking Statement This presentation contains forward-looking statements, including: statements about our plans to develop

More information

Chapter 1: Data Collection Pearson Prentice Hall. All rights reserved

Chapter 1: Data Collection Pearson Prentice Hall. All rights reserved Chapter 1: Data Collection 2010 Pearson Prentice Hall. All rights reserved 1-1 Statistics is the science of collecting, organizing, summarizing, and analyzing information to draw conclusions or answer

More information

Development of restricted mean survival time difference in network metaanalysis based on data from MACNPC update.

Development of restricted mean survival time difference in network metaanalysis based on data from MACNPC update. Development of restricted mean survival time difference in network metaanalysis based on data from MACNPC update. Claire Petit, Pierre Blanchard, Jean-Pierre Pignon, Béranger Lueza June 2017 CONTENTS Context...

More information

Content. Basic Statistics and Data Analysis for Health Researchers from Foreign Countries. Research question. Example Newly diagnosed Type 2 Diabetes

Content. Basic Statistics and Data Analysis for Health Researchers from Foreign Countries. Research question. Example Newly diagnosed Type 2 Diabetes Content Quantifying association between continuous variables. Basic Statistics and Data Analysis for Health Researchers from Foreign Countries Volkert Siersma siersma@sund.ku.dk The Research Unit for General

More information

Describe what is meant by a placebo Contrast the double-blind procedure with the single-blind procedure Review the structure for organizing a memo

Describe what is meant by a placebo Contrast the double-blind procedure with the single-blind procedure Review the structure for organizing a memo Please note the page numbers listed for the Lind book may vary by a page or two depending on which version of the textbook you have. Readings: Lind 1 11 (with emphasis on chapters 10, 11) Please note chapter

More information

Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events

Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts Future Cardiovascular Events Diabetes Care Publish Ahead of Print, published online May 28, 2008 Chronotropic response in patients with diabetes Impaired Chronotropic Response to Exercise Stress Testing in Patients with Diabetes Predicts

More information

Methodology for Statistical Analysis of

Methodology for Statistical Analysis of Environmental Health Perspectives Vol. 68, pp. 5-9, 1986 Methodology for Statistical Analysis of SENCAR Mouse Skin Assay Data by Judy A. Stober* Various response measures and statistical methods appropriate

More information

Section 3: Economic evaluation

Section 3: Economic evaluation Section 3: Economic evaluation PERSPECTIVES OF AN EVALUATOR DR BONNY PARKINSON SENIOR RESEARCH FELLOW MACQUARIE UNIVERSITY CENTRE FOR THE HEALTH ECONOMY (MUCHE) Disclaimer The views presented are my own

More information

Overview. Goals of Interpretation. Methodology. Reasons to Read and Evaluate

Overview. Goals of Interpretation. Methodology. Reasons to Read and Evaluate Overview Critical Literature Evaluation and Biostatistics Ahl Ashley N. Lewis, PharmD, BCPS Clinical Specialist, Drug Information UNC Hospitals Background Review of basic statistics Statistical tests Clinical

More information

SYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT

SYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase

More information

Still important ideas

Still important ideas Readings: OpenStax - Chapters 1 11 + 13 & Appendix D & E (online) Plous - Chapters 2, 3, and 4 Chapter 2: Cognitive Dissonance, Chapter 3: Memory and Hindsight Bias, Chapter 4: Context Dependence Still

More information

Individual Study Table Referring to Part of Dossier: Volume: Page:

Individual Study Table Referring to Part of Dossier: Volume: Page: Synopsis Abbott Laboratories Name of Study Drug: Paricalcitol Capsules (ABT-358) (Zemplar ) Name of Active Ingredient: Paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For

More information

Advanced Decision Analysis: Markov Models

Advanced Decision Analysis: Markov Models Advanced Decision Analysis: Markov Models Reasons to understand Markov models It s the standard in academia Very powerful/flexible tool simple decision trees relatively inflexible limited time frame hard

More information

PRINCIPLES OF STATISTICS

PRINCIPLES OF STATISTICS PRINCIPLES OF STATISTICS STA-201-TE This TECEP is an introduction to descriptive and inferential statistics. Topics include: measures of central tendency, variability, correlation, regression, hypothesis

More information

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current

More information

Diagnostic methods 2: receiver operating characteristic (ROC) curves

Diagnostic methods 2: receiver operating characteristic (ROC) curves abc of epidemiology http://www.kidney-international.org & 29 International Society of Nephrology Diagnostic methods 2: receiver operating characteristic (ROC) curves Giovanni Tripepi 1, Kitty J. Jager

More information

Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma

Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Comprehensive Research Plan: Inhaled corticosteroids + long-acting beta agonists (ICS+LABA) for the treatment of asthma Pharmacoepidemiology Unit July 10, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca

More information

A statistical evaluation of the effects of gender differences in assessment of acute inhalation toxicity

A statistical evaluation of the effects of gender differences in assessment of acute inhalation toxicity A statistical evaluation of the effects of gender differences in assessment of acute inhalation toxicity Human and Experimental Toxicology 30(3) 217 238 ª The Author(s) 2010 Reprints and permission: sagepub.co.uk/journalspermissions.nav

More information

Age-standardised Net Survival & Cohort and Period Net Survival Estimates

Age-standardised Net Survival & Cohort and Period Net Survival Estimates Cancer survival analysis using population-based data Granada, 27-28 March 2017 Age-standardised Net Survival & Cohort and Period Net Survival Estimates Cancer survival analysis using population-based data

More information

PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES

PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES PERCUTANEOUS STRUCTURAL UPDATES TAVR WATCHMAN(LEFT ATRIAL APPENDAGE OCCLUDERS) MITRACLIP PARAVALVULAR LEAK REPAIRS ASD/PFO CLOSURES VALVULOPLASTIES Dr.Vinny K.Ram No disclosures TAVR 1 Lesson number 1:

More information

Nivolumab Addendum to Commission A

Nivolumab Addendum to Commission A IQWiG Reports Commission No. A15-58 Nivolumab Addendum to Commission A15-32 1 Addendum Commission:A15-58 Version: 1.0 Status: 13 January 2016 1 Translation of addendum A15-58 Nivolumab Addendum zum Auftrag

More information

Normal Distribution: Homework *

Normal Distribution: Homework * OpenStax-CNX module: m16978 1 Normal Distribution: Homework * Susan Dean Barbara Illowsky, Ph.D. This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution License 2.0 Exercise

More information

Nature Genetics: doi: /ng Supplementary Figure 1. Details of sequencing analysis.

Nature Genetics: doi: /ng Supplementary Figure 1. Details of sequencing analysis. Supplementary Figure 1 Details of sequencing analysis. (a) Flow chart showing which patients fall into each category and were used for analysis. (b) Graph showing the average and median coverage for all

More information

Biostatistics. Donna Kritz-Silverstein, Ph.D. Professor Department of Family & Preventive Medicine University of California, San Diego

Biostatistics. Donna Kritz-Silverstein, Ph.D. Professor Department of Family & Preventive Medicine University of California, San Diego Biostatistics Donna Kritz-Silverstein, Ph.D. Professor Department of Family & Preventive Medicine University of California, San Diego (858) 534-1818 dsilverstein@ucsd.edu Introduction Overview of statistical

More information

Author's response to reviews

Author's response to reviews Author's response to reviews Title: Characteristic mtor activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease - a combined tissue microarray, in vitro and in vivo study

More information